Quick-Med Gets Three Patents for its Novel PU-Modified Polycation Used in Adhesives

GAINESVILLE, Florida -- Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced advances in patent coverage in Australia, China, and Mexico for the Companys novel, non-leaching NIMBUS antimicrobial technology.

The Australian Patent Office and the patent office of Mexico, Instituto Mexicano de la Propiedad Industrial, have granted Quick-Med Technologies pending patent entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers" in their respective jurisdictions. Additionally, the State Intellectual Property of the Peoples Republic of China has issued a "Notification to Grant an Invention Patent" for this pending patent in China. These new patents will significantly expand the international intellectual property coverage for NIMBUS.

The three new patents are similar to U.S. Patent No. 8,088,400, also entitled "Disinfectant with Quaternary Ammonium Polymer and Copolymers". They cover the Companys novel polyurethane-modified polycation, the newest member of the NIMBUS technology family of antimicrobials. NIMBUS technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation built into the backbone of various polymers, in this case, polyurethane.

The new patents are key "composition-of-matter" patents that cover the incorporation of a NIMBUS polycation into the main chain of a urethane polymer. The physical state of the polyurethane polycation can be modified to alter the strength of the antimicrobial, the breathability of the film or coating and its flexibility or rigidity. The patents provide protection for various claims regarding the efficacy and durability of an antimicrobial polyurethane.

"This patent adds an exciting new dimension to our NIMBUS technology," says Dr. William Toreki, co-inventor and Quick-Meds vice president of Research & Development. "Our new polyurethane polycation is well suited for a wide range of applications including films and coatings, adhesives, catheters and other types of extruded tubing, and as a durable hand sanitizer."

"These NIMBUS patents are strategically important because they significantly expand the global coverage for our proprietary NIMBUS technology," said Dr. Bernd Liesenfeld, Quick-Meds president. "They protect the underlying chemistry for several of our cutting-edge developments including applications for advanced wound dressings, medical adhesives, and catheters."

NIMBUS technology employs a safe, eco-friendly active agent that remains in full concentration on any of several substrates. It controls a broad range of both Gram-positive and Gram-negative bacteria. NIMBUS antimicrobials are not depleted in use, maintain effectiveness even in the presence of large amounts of blood or body fluids, and by design, pose no risk of bacteria developing resistance.

NIMBUS bonded antimicrobial technology was cleared by the FDA in 2009 and is the only bonded antimicrobial technology available in wound dressings. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts.

* NIMBUS and Stay Fresh are registered trademarks and NimbuDerm is a trademark of Quick-Med Technologies, Inc.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the healthcare and consumer markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm technology is being developed as a long-lasting hand sanitizer.

Forward looking statements

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Companys filings with the Securities and Exchange Commission ("SEC") which may be accessed at the SECs Edgar System at www.sec.gov.

Source: Quick-Med Technologies